SYRS - Syros Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
SYRS price evolution
SYRS
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $141.65 | $115.31 | $118.53 | $107.85 |
| Short term investments | $28.54 | $61.04 | ||
| Net receivables | $1.67 | $1.76 | $1.76 | |
| Inventory | ||||
| Total current assets | $144.98 | $122.52 | $152.63 | $173.64 |
| Long term investments | ||||
| Property, plant & equipment | $19.48 | $20.08 | $23.04 | $23.95 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $23.19 | $25.28 | $28.35 | $31.68 |
| Total investments | $28.54 | $61.04 | ||
| Total assets | $168.17 | $147.79 | $180.98 | $205.32 |
| Current liabilities | ||||
| Accounts payable | $11.54 | $2.85 | $6.69 | $2.79 |
| Deferred revenue | $0.14 | $2.19 | $3.25 | |
| Short long term debt | $8.99 | $3.91 | $2.17 | $3.76 |
| Total current liabilities | $36.68 | $28.39 | $28.38 | $23.55 |
| Long term debt | $53.08 | $58.55 | $60.66 | $59.41 |
| Total noncurrent liabilities | $114.83 | $83.1 | $79.37 | $75.02 |
| Total debt | $62.08 | $62.46 | $62.83 | $63.17 |
| Total liabilities | $151.51 | $111.49 | $107.74 | $98.57 |
| Shareholders' equity | ||||
| Retained earnings | -$722.81 | -$658.42 | -$618.28 | -$582.02 |
| Other shareholder equity | $0.05 | $0.26 | ||
| Total shareholder equity | $16.66 | $36.3 | $73.24 | $106.75 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $141.65 | $170.55 | $95.39 | $173.98 |
| Short term investments | $34.84 | $38.07 | ||
| Net receivables | $1.69 | $2.98 | $2.3 | |
| Inventory | ||||
| Total current assets | $144.98 | $211.39 | $136.59 | $178.6 |
| Long term investments | $13.04 | $3.09 | ||
| Property, plant & equipment | $19.48 | $24.66 | $27.29 | $29.6 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $23.19 | $33.09 | $46.35 | $34.69 |
| Total investments | $34.84 | $51.1 | $3.09 | |
| Total assets | $168.17 | $244.49 | $182.94 | $213.3 |
| Current liabilities | ||||
| Accounts payable | $11.54 | $6.41 | $3.69 | $3.6 |
| Deferred revenue | $4.33 | $10.18 | $22.09 | |
| Short long term debt | $8.99 | $2.07 | $2.01 | $1.73 |
| Total current liabilities | $36.68 | $30.78 | $31.51 | $28.6 |
| Long term debt | $53.08 | $40.65 | $40.32 | $39.9 |
| Total noncurrent liabilities | $114.83 | $85.97 | $66.21 | $94.07 |
| Total debt | $62.08 | $63.57 | $65.19 | $66.21 |
| Total liabilities | $151.51 | $116.75 | $97.72 | $122.7 |
| Shareholders' equity | ||||
| Retained earnings | -$722.81 | -$558.23 | -$463.58 | -$377 |
| Other shareholder equity | $0.1 | -$0.08 | ||
| Total shareholder equity | $16.66 | $127.74 | $85.22 | $90.55 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.39 | $3.76 | $2.83 | $2.95 |
| Cost of revenue | ||||
| Gross Profit | $0.39 | $3.76 | $2.83 | $2.95 |
| Operating activities | ||||
| Research & development | $21.5 | $28.28 | $29.61 | $28.76 |
| Selling, general & administrative | $5.89 | $7.76 | $7.22 | $7.41 |
| Total operating expenses | $27.53 | $38.4 | $36.83 | $36.17 |
| Operating income | -$27.14 | -$34.64 | -$34 | -$33.21 |
| Income from continuing operations | ||||
| EBIT | -$63.05 | -$38.84 | -$34.98 | -$22.57 |
| Income tax expense | ||||
| Interest expense | $1.33 | $1.3 | $1.28 | $1.22 |
| Net income | ||||
| Net income | -$64.38 | -$40.14 | -$36.26 | -$23.79 |
| Income (for common shares) | -$64.38 | -$40.14 | -$36.26 | -$23.79 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.94 | $14.88 | $23.49 | $15.09 |
| Cost of revenue | ||||
| Gross Profit | $9.94 | $14.88 | $23.49 | $15.09 |
| Operating activities | ||||
| Research & development | $108.15 | $111.94 | $99.87 | $76.06 |
| Selling, general & administrative | $28.28 | $29.3 | $23.04 | $21.32 |
| Total operating expenses | $138.92 | $150.75 | $122.91 | $97.39 |
| Operating income | -$128.99 | -$135.87 | -$99.42 | -$82.3 |
| Income from continuing operations | ||||
| EBIT | -$159.45 | -$90.52 | -$82.65 | -$82.25 |
| Income tax expense | ||||
| Interest expense | $5.13 | $4.13 | $3.91 | $1.79 |
| Net income | ||||
| Net income | -$164.57 | -$94.65 | -$86.56 | -$84.04 |
| Income (for common shares) | -$164.57 | -$94.65 | -$86.56 | -$84.04 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$64.38 | -$40.14 | -$36.26 | -$23.79 |
| Operating activities | ||||
| Depreciation | $0.35 | $0.62 | $0.65 | $0.7 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.72 | $3.25 | $2.81 | $2.65 |
| Total cash flows from operations | -$18.56 | -$31.86 | -$22.39 | -$36.9 |
| Investing activities | ||||
| Capital expenditures | $1.52 | $0 | -$0.23 | |
| Investments | $28.64 | $32.92 | -$25.51 | |
| Total cash flows from investing | $1.52 | $28.64 | $32.92 | -$25.75 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $43.38 | $0.14 | ||
| Net borrowings | -$0 | -$0.01 | -$0 | -$0.05 |
| Total cash flows from financing | $43.38 | -$0.01 | $0.14 | -$0.05 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $26.34 | -$3.22 | $10.68 | -$62.7 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$164.57 | -$94.65 | -$86.56 | -$84.04 |
| Operating activities | ||||
| Depreciation | $2.33 | $2.97 | $3.02 | $2.77 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $10.43 | $11.41 | $10.35 | $10.94 |
| Total cash flows from operations | -$109.71 | -$123.06 | -$99.54 | -$57.36 |
| Investing activities | ||||
| Capital expenditures | $1.29 | -$1.24 | -$1.25 | -$3.34 |
| Investments | $36.05 | $68.43 | -$51.41 | $50 |
| Total cash flows from investing | $37.34 | $67.19 | -$52.65 | $46.66 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $43.53 | $119.9 | $70.82 | $103.78 |
| Net borrowings | -$0.07 | -$0.59 | -$0.27 | $39.38 |
| Total cash flows from financing | $43.46 | $131.04 | $70.51 | $142.95 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$28.91 | $75.17 | -$81.68 | $132.25 |
News
Fundamentals
| Market cap | $135.95M |
|---|---|
| Enterprise value | $56.38M |
| Shares outstanding | 26.45M |
| Revenue | $9.94M |
|---|---|
| EBITDA | -$157.12M |
| EBIT | -$159.45M |
| Net Income | -$164.57M |
| Revenue Q/Q | -151.19% |
| Revenue Y/Y | -33.23% |
| P/E ratio | -0.83 |
|---|---|
| EV/Sales | 5.67 |
| EV/EBITDA | -0.36 |
| EV/EBIT | -0.35 |
| P/S ratio | 13.68 |
| P/B ratio | 8.16 |
| Book/Share | 0.63 |
| Cash/Share | 5.36 |
| EPS | -$6.22 |
|---|---|
| ROA | -93.74% |
| ROE | -282.58% |
| Debt/Equity | 9.09 |
|---|---|
| Net debt/EBITDA | -0.06 |
| Current ratio | 3.95 |
| Quick ratio | 3.95 |